January 30, 2023
Officers and directors of biopharmaceutical company Axsome Therapeutics Inc. were hit with a derivative shareholder suit in New York federal court over claims that they hid issues about Axsome's latest drug that were later pointed out by the U.S. Food and Drug Administration, causing a significant stock price drop.